-
Product Insights
NewIschemia Reperfusion Injury – Drugs In Development, 2024
Empower your strategies with our Ischemia Reperfusion Injury – Drugs In Development, 2024 report and make more profitable business decisions. Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension,...
-
Product Insights
NewCognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-248 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-248 in Solid Tumor Drug Details: AB-248 is under development for the treatment of locally...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MZE-001 in Pompe Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MZE-001 in Pompe Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MZE-001 in Pompe Disease Drug Details:MZE-001 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aminolevulinic Acid Hydrochloride in Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aminolevulinic Acid Hydrochloride in Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Aminolevulinic Acid Hydrochloride in Anemia Drug Details:Aminolevulinic acid hydrochloride (5-ALA) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aminolevulinic Acid Hydrochloride in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aminolevulinic Acid Hydrochloride in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Aminolevulinic Acid Hydrochloride in Mild Cognitive ImpairmentDrug Details:Aminolevulinic acid hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-7789 in Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-7789 in Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-7789 in Non-Small Cell Lung Carcinoma Drug Details: AZD-7789 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YT-1920 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YT-1920 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR)...